Many intervention studies use experimental agents that are not (yet) tested for pre-clinical use. To be (potentially) efficacious, an agent should at least reach its target in pharmacologically meaningful quantities. In order to address this issue, we conduct pharmacokinetic studies using plasma and tissues. The sensitivity and selectivity of our LC-MS/MS systems usually allows the use of small samples volumes (5-10 μl) and minimal sample pretreatment, while still providing accurate data. This enables us to setup and validate assays for novel compounds in a relative short time frame. Moreover, it allows us to perform analyses on tail vein blood samples that can be drawn serially and thereby obtain full pharmacokinetic plasma concentration – time curves from one animal adhering to the standards of the three R’s in animal research.
However, in many cases, there is a need to test combinations of agents of different sources without restrictions. We, therefore often purchase such agents from stocks of companies. Alternatively, we can have compounds through custom synthesis. Currently, we hold approximately 100 different drugs in quantities between 20 mg to 100 g quantities. Next to that we develop and/or provide advise what may be the most suitable formulation of such agents that can be used in animal studies. We perform studies to demonstrate the stability of drug formulations. We formulate and deliver drugs for preclinical studies performed by the intervention unit.
